title: Use of TAGVHD warnings in patients receiving purine analogue chemotherapy.
authors.forename: F J
authors.initials: FJ
authors.lastname: Cutler
authors.forename: C
authors.initials: C
authors.lastname: Niciu
authors.forename: J A
authors.initials: JA
authors.lastname: Murphy
authors.forename: R L
authors.initials: RL
authors.lastname: Soutar
mesh_terms: D001803:Blood Transfusion / Q000401:mortality; D004791:Enzyme Inhibitors / Q000009:adverse effects; D006086:Graft vs Host Disease / Q000209:etiology* / Q000517:prevention & control*; D006291:Health Policy; D006801:Humans; D012189:Retrospective Studies; D012307:Risk Factors; D065227:Transfusion Reaction; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D004791:Enzyme Inhibitors; D014740:Vidarabine; C024352:fludarabine